In March 2025, Shandong Suncadia Medicine Co., Ltd. conducted a phase II Clinical Study of Efficacy and Safety of HRS-1780 ...

In this video, Girish N Nadkarni, MD, a professor of medicine at the Icahn School of Medicine at Mount Sinai, discusses recent advancements in chronic kidney disease care.

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Announced the acceptance of the New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for OLC for the treatment of hyperphosphatemia in patients with CKD on dialysis. The FDA set a ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

The FDA has granted a speedy review of Eli Lilly ... to reduce the risk of renal failure and cardiovascular death in people with chronic kidney disease (CKD). The new indication could unlock ...

Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...

PRINCETON, NJ, USA & TOKYO, Japan I March 31, 2025 I Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd.